Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Other Non-Current Assets (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Other Non-Current Assets data on record, last reported at $303000.0 in Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 88.2% year-over-year to $303000.0; the TTM value through Dec 2025 reached $303000.0, down 88.2%, while the annual FY2025 figure was $303000.0, 88.2% down from the prior year.
  • Other Non-Current Assets reached $303000.0 in Q4 2025 per TNGX's latest filing, up from $290000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $4.0 million in Q1 2022 and bottomed at $1000.0 in Q1 2025.
  • Average Other Non-Current Assets over 5 years is $2.1 million, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 28425.0% in 2023, then tumbled 99.96% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.7 million in 2021, then surged by 133.64% to $4.0 million in 2022, then dropped by 15.0% to $3.4 million in 2023, then decreased by 24.5% to $2.6 million in 2024, then tumbled by 88.2% to $303000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $303000.0 in Q4 2025, $290000.0 in Q3 2025, and $2.1 million in Q2 2025.